MBQ 167
Alternative Names: MBQ-167Latest Information Update: 22 Jun 2024
Price :
$50 *
At a glance
- Originator University of Puerto Rico
- Developer MBQ Pharma
- Class Antineoplastics; Benzene derivatives; Carbazoles; Small molecules; Triazoles
- Mechanism of Action Rac GTP-binding protein inhibitors; Rho GTP-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Breast cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Breast cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Oct 2023 Phase-I clinical trials in Breast cancer (Late-stage disease, Second-line therapy or greater) in Puerto Rico (PO) (NCT06075810)
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in glioblastoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)